The CROs will become part of a clinical studies network to develop vaccines, drugs, and diagnostics against chemical, biological radiological, nuclear, pandemic flu and emerging infectious diseases.
The federal funds were doled out in five-year, $100m contracts. BARDA also anticipates spending $79m on its Broad Spectrum Antimicrobials program in FY 2015.
PPD’s contract with BARDA is an indefinite-delivery, indefinite-quantity (IDIQ) agreement for clinical study services, with a minimum period of performance of two years and maximum period of performance of five years.
Paul Colvin, PPD’s EVP of clinical development said: “We are excited at the prospect of deploying our world-class scientific expertise, innovative solutions, cutting-edge technology, flexible resources and operational efficiencies to help protect public health and the nation’s health security.”
Victoria Tifft, CEO of ClinicalRM, added: “ClinicalRM is proud to engage in this critical work with BARDA. The award of this contract allows us to continue to build strong and meaningful partnerships with the Government, industry, and academia to combat a variety of potential national threats.”